================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Ilex Oncology Inc.
------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.01 per share
------------------------------------------------------
(Title of Class of Securities)
451923106
------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
================================================================================
Page 1 of 13 Pages
<PAGE>
CUSIP No. 451923106 Page 2 of 13 Pages
- --------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
Perseus, L.L.C.
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
52-1970543
- --------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |x|
(b) | |
- --------------------------------------------------------------------------------
(3) SEC USE ONLY
- --------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
(5) SOLE VOTING POWER
678,206
------------------------------------------------------
NUMBER OF SHARES (6) SHARED VOTING POWER
BENEFICIALLY OWNED 0
BY EACH ------------------------------------------------------
REPORTING PERSON (7) SOLE DISPOSITIVE POWER
WITH 678,206
------------------------------------------------------
(8) SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
841,883
- --------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
| |
- --------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.8%
- --------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 451923106 Page 3 of 13 Pages
- --------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
Frank H. Pearl
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
- --------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |x|
(b) | |
- --------------------------------------------------------------------------------
(3) SEC USE ONLY
- --------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
(5) SOLE VOTING POWER
678,206
------------------------------------------------------
NUMBER OF SHARES (6) SHARED VOTING POWER
BENEFICIALLY OWNED 0
BY EACH ------------------------------------------------------
REPORTING PERSON (7) SOLE DISPOSITIVE POWER
WITH 678,206
------------------------------------------------------
(8) SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
841,883
- --------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
| |
- --------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.8%
- --------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 451923106 Page 4 of 13 Pages
- --------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
Perseus Pharmaceuticals, L.L.C.
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
52-2021673
- --------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |x|
(b) | |
- --------------------------------------------------------------------------------
(3) SEC USE ONLY
- --------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
(5) SOLE VOTING POWER
654,706
------------------------------------------------------
NUMBER OF SHARES (6) SHARED VOTING POWER
BENEFICIALLY OWNED 0
BY EACH ------------------------------------------------------
REPORTING PERSON (7) SOLE DISPOSITIVE POWER
WITH 654,706
------------------------------------------------------
(8) SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
818,383
- --------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
| |
- --------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.7%
- --------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 451923106 Page 5 of 13 Pages
- --------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
Perseus Capital, L.L.C.
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
52-2032190
- --------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |x|
(b) | |
- --------------------------------------------------------------------------------
(3) SEC USE ONLY
- --------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
(5) SOLE VOTING POWER
23,500
------------------------------------------------------
NUMBER OF SHARES (6) SHARED VOTING POWER
BENEFICIALLY OWNED 0
BY EACH ------------------------------------------------------
REPORTING PERSON (7) SOLE DISPOSITIVE POWER
WITH 23,500
------------------------------------------------------
(8) SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
23,500
- --------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
| |
- --------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.2%
- --------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
CUSIP No. 451923106 Page 6 of 13 Pages
Item 1. (a) Name of Issuer:
Ilex Oncology Inc.
(b) Address of Issuer's Principal Executive Offices:
11500 I.H. 10 West
Suite 300
San Antonio, Texas 78230
Item 2. (a) - (c) Name, Address of Principal Business Office, or if None,
Residence, and Citizenship of Persons Filing. This statement
is filed on behalf of the persons named in paragraphs 1
through 4 below (collectively, the "Reporting Persons") and
their written agreement to the joint filing of this statement
is attached hereto as Exhibit A. The following information is
furnished with respect to each of the Reporting Persons.
1. Perseus, L.L.C.
Business Address:
1627 I Street, N.W.
Suite 610
Washington, D.C. 20006
Place of Organization: Delaware
2. Frank H. Pearl
Business Address:
c/o Perseus, L.L.C.
1627 I Street, N.W.
Suite 610
Washington, D.C. 20006
Citizenship: United States
<PAGE>
CUSIP No. 451923106 Page 7 of 13 Pages
3. Perseus Pharmaceuticals, L.L.C. (1)
Business Address:
1627 I Street, N.W.
Suite 610
Washington, D.C. 20006
Place of Organization: Delaware
4. Perseus Capital, L.L.C. (2)
Business Address:
1627 I Street, N.W.
Suite 610
Washington, D.C. 20006
Place of Organization: Delaware
(d) Title of Class of Securities:
Common Stock, par value $.01 per share.
(e) CUSIP Number:
451923106
- ----------------
(1) Perseus Pharmaceuticals, L.L.C. is an investment fund managed by Perseus,
L.L.C.
(2) Perseus Capital, L.L.C. is an investment fund managed indirectly by Perseus,
L.L.C.
<PAGE>
CUSIP No. 451923106 Page 8 of 13 Pages
Item 3.
Not Applicable.
Item 4. Ownership.
The aggregate number and percentage of outstanding shares of common
stock, par value $.01 per share, of Ilex Oncology, Inc. (the "Shares")
beneficially owned by each of the Reporting Persons are set forth below.
1. Perseus, L.L.C. (3)
(a) Amount Beneficially Owned: 841,883
(b) Percent of Class: 6.8%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 678,206
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition
of: 678,206
(iv) shared power to dispose or to direct the disposition
of: 0
- ----------------
(3) Perseus, L.L.C is the sole manager of Perseus Pharmaceuticals, L.L.C.
and the sole manager, indirectly, of Perseus Capital, L.L.C. The amounts
reported as beneficially owned by Perseus, L.L.C. consist of 818,383 shares
beneficially owned by Perseus Pharmaceuticals, L.L.C. and 23,500 shares
beneficially owned by Perseus Capital, L.L.C.
<PAGE>
CUSIP No. 451923106 Page 9 of 13 Pages
2. Frank H. Pearl (4)
(a) Amount Beneficially Owned: 841,883
(b) Percent of Class: 6.8%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 678,206
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition
of: 678,206
(iv) shared power to dispose or to direct the disposition
of: 0
- ----------------
(4) Frank H. Pearl is the controlling person of Perseus, L.L.C, a Delaware
limited liability company that, in turn, is the sole manager of Perseus
Pharmaceuticals, L.L.C. and the sole manager, indirectly, of Perseus
Capital, L.L.C. The amounts reported as beneficially owned by Mr. Pearl
consist of 818,383 shares beneficially owned by Perseus Pharmaceuticals,
L.L.C. and 23,500 shares beneficially owned by Perseus Capital, L.L.C.
<PAGE>
CUSIP No. 451923106 Page 10 of 13 Pages
3. Perseus Pharmaceuticals, L.L.C.
(a) Amount Beneficially Owned: 818,383 (5)
(b) Percent of Class: 6.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 654,706
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition
of: 654,706
(iv) shared power to dispose or to direct the disposition
of: 0
- ----------------
(5) Includes 163,677 shares that are subject to warrants held by Perseus
Pharmaceuticals, L.L.C. that are exercisable within 60 days.
4. Perseus Capital, L.L.C.
(a) Amount Beneficially Owned: 23,500
(b) Percent of Class: 0.2%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 23,500
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition
of: 23,500
(iv) shared power to dispose or to direct the disposition
of: 0
Item 5. Ownership of Five Percent or Less of a Class.
Not Applicable.
<PAGE>
CUSIP No. 451923106 Page 11 of 13 Pages
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7. Identification and Classification of the Subsidiary which Acquired
the Security Being Reported on By the Parent Holding Company.
Not Applicable.
<PAGE>
CUSIP No. 451923106 Page 12 of 13 Pages
Item 8. Identification and Classification of Members of the Group.
The identity of each member of the group is set forth in Exhibit B
hereto.
Item 9. Notice of Dissolution of Group.
Not Applicable.
Item 10. Certification.
Not Applicable.
<PAGE>
CUSIP No. 451923106 Page 13 of 13 Pages
SIGNATURES
After reasonable inquiry and to the best of the knowledge and belief of
each of the undersigned, each of the undersigned certifies that the information
set forth in this statement is true, complete and correct.
Dated: February 13, 1998
PERSEUS, L.L.C.
By: /s/ Kenneth M. Socha
-------------------------------
Kenneth M. Socha
Executive Vice President
/s/ Frank H. Pearl
-------------------------------
FRANK H. PEARL
PERSEUS PHARMACEUTICALS, L.L.C.
By: /s/ Kenneth M. Socha
-------------------------------
Kenneth M. Socha
Executive Vice President
PERSEUS CAPITAL, L.L.C.
By: /s/ Kenneth M. Socha
-------------------------------
Kenneth M. Socha
Executive Vice President
<PAGE>
Exhibit A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934,
as amended, the persons named below hereby agree to the joint filing on behalf
of each of them of a Statement on Schedule 13G (including amendments thereto)
with respect to the common stock, par value $.01 per share, of Ilex Oncology
Inc. and further agree that this Joint Filing Agreement be included as an
Exhibit to such statement.
IN WITNESS WHEREOF, the undersigned have executed this Joint Filing
Agreement as of February 13, 1998.
PERSEUS, L.L.C.
By: /s/ Kenneth M. Socha
-------------------------------
Kenneth M. Socha
Executive Vice President
/s/ Frank H. Pearl
-------------------------------
FRANK H. PEARL
PERSEUS PHARMACEUTICALS, L.L.C.
By: /s/ Kenneth M. Socha
-------------------------------
Kenneth M. Socha
Executive Vice President
PERSEUS CAPITAL, L.L.C.
By: /s/ Kenneth M. Socha
-------------------------------
Kenneth M. Socha
Executive Vice President
<PAGE>
Exhibit B
IDENTIFICATION OF MEMBERS OF THE GROUP
This Statement on Schedule 13G is filed on behalf of a group consisting of
the following members:
Perseus, L.L.C.
Frank H. Pearl
Perseus Pharmaceuticals, L.L.C.
Perseus Capital, L.L.C.
